Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Aug 22;382(6593):722-5.
doi: 10.1038/382722a0.

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

Affiliations

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

M Samson et al. Nature. .

Abstract

HIV-1 and related viruses require co-receptors, in addition to CD4, to infect target cells. The chemokine receptor CCR-5 (ref.1) was recently demonstrated to be a co-receptor for macrophage-tropic (M-tropic) HIV-1 strains, and the orphan receptor LESTR (also called fusin) allows infection by strains adapted for growth in transformed T-cell lines (T-tropic strains). Here we show that a mutant allele of CCR-5 is present at a high frequency in caucasian populations (allele frequency, 0.092), but is absent in black populations from Western and Central Africa and Japanese populations. A 32-base-pair deletion within the coding region results in a frame shift, and generates a non-functional receptor that does not support membrane fusion or infection by macrophage- and dual-tropic HIV-1 strains. In a cohort of HIV-1 infected caucasian subjects, no individual homozygous for the mutation was found, and the frequency of heterozygotes was 35% lower than in the general population. White blood cells from an individual homozygous for the null allele were found to be highly resistant to infection by M-tropic HIV-1 viruses, confirming that CCR-5 is the major co-receptor for primary HIV-1 strains. The lower frequency of heterozygotes in seropositive patients may indicate partial resistance.

PubMed Disclaimer

Comment in

  • Natural resistance to HIV?
    Hill CM, Littman DR. Hill CM, et al. Nature. 1996 Aug 22;382(6593):668-9. doi: 10.1038/382668a0. Nature. 1996. PMID: 8751431 No abstract available.

Similar articles

Cited by

  • Maraviroc - A CCR5 Antagonist for the Treatment of HIV-1 Infection.
    Van Der Ryst E. Van Der Ryst E. Front Immunol. 2015 Jun 5;6:277. doi: 10.3389/fimmu.2015.00277. eCollection 2015. Front Immunol. 2015. PMID: 26097475 Free PMC article. Review. No abstract available.
  • Hematopoietic cell transplantation with cord blood for cure of HIV infections.
    Petz LD, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Tonai R, Santos S, Bravo A, Spellman S, Gragert L, Rossi J, Li S, Li H, Senitzer D, Zaia J, Rosenthal J, Forman S, Chow R. Petz LD, et al. Biol Blood Marrow Transplant. 2013 Mar;19(3):393-7. doi: 10.1016/j.bbmt.2012.10.017. Epub 2012 Oct 23. Biol Blood Marrow Transplant. 2013. PMID: 23089564 Free PMC article.
  • The CCR5Δ32 polymorphism in Brazilian patients with sickle cell disease.
    Lopes MP, Santos MN, Faber EW, Bezerra MA, Hatzlhofer BL, Albuquerque DM, Zaccariotto TR, Ribeiro DM, Araújo Ada S, Costa FF, Sonati Mde F. Lopes MP, et al. Dis Markers. 2014;2014:678246. doi: 10.1155/2014/678246. Epub 2014 Nov 11. Dis Markers. 2014. PMID: 25548430 Free PMC article.
  • Multicohort genomewide association study reveals a new signal of protection against HIV-1 acquisition.
    Limou S, Delaneau O, van Manen D, An P, Sezgin E, Le Clerc S, Coulonges C, Troyer JL, Veldink JH, van den Berg LH, Spadoni JL, Taing L, Labib T, Montes M, Delfraissy JF, Schachter F, O'Brien SJ, Buchbinder S, van Natta ML, Jabs DA, Froguel P, Schuitemaker H, Winkler CA, Zagury JF. Limou S, et al. J Infect Dis. 2012 Apr 1;205(7):1155-62. doi: 10.1093/infdis/jis028. Epub 2012 Feb 23. J Infect Dis. 2012. PMID: 22362864 Free PMC article.
  • A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.
    Lane J, McLaren PJ, Dorrell L, Shianna KV, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman MT, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs PH, Brand B, Brown D, Chiang E, Cid-Haro AR, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris DA, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee TT, Wolinsky SM, Martinson J, Hussain SK, Bream JH, Jacobson LP, Carrington M, Goedert JJ, Haynes BF, McMichael AJ, Goldstein DB, Fellay J; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). Lane J, et al. Hum Mol Genet. 2013 May 1;22(9):1903-10. doi: 10.1093/hmg/ddt033. Epub 2013 Jan 30. Hum Mol Genet. 2013. PMID: 23372042 Free PMC article.

Publication types

MeSH terms

Associated data